Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 107 articles:
HTML format
Text format



Single Articles


    December 2018
  1. GRIONI S, Agnoli C, Krogh V, Pala V, et al
    Dietary cadmium and risk of breast cancer subtypes defined by hormone receptor status: a prospective cohort study.
    Int J Cancer. 2018 Dec 4. doi: 10.1002/ijc.32039.
    PubMed     Text format     Abstract available


    November 2018
  2. TORRES D, Lorenzo Bermejo J, Garcia Mesa K, Gilbert M, et al
    Interaction between genetic ancestry and common breast cancer susceptibility variants in Colombian women.
    Int J Cancer. 2018 Nov 28. doi: 10.1002/ijc.32023.
    PubMed     Text format     Abstract available


  3. PANDEY K, An HJ, Kim SK, Lee SA, et al
    Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review.
    Int J Cancer. 2018 Nov 26. doi: 10.1002/ijc.32020.
    PubMed     Text format     Abstract available


  4. KLASCHIK K, Hauke J, Neidhardt G, Trankle C, et al
    The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers.
    Int J Cancer. 2018 Nov 26. doi: 10.1002/ijc.32016.
    PubMed     Text format    


  5. BULANOVA DR, Helenius M, Sokolenko AP, Kuznetsov SG, et al
    Response to: The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers.
    Int J Cancer. 2018 Nov 25. doi: 10.1002/ijc.32013.
    PubMed     Text format    


  6. PEREIRA-VEIGA T, Abreu M, Robledo D, Matias-Guiu X, et al
    CTCs-derived xenograft development in a Triple Negative breast cancer case.
    Int J Cancer. 2018 Nov 19. doi: 10.1002/ijc.32001.
    PubMed     Text format     Abstract available


  7. YUAN B, Schafferer S, Tang Q, Scheffler M, et al
    A plasma metabolite panel as biomarkers for early primary breast cancer detection.
    Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31996.
    PubMed     Text format     Abstract available


  8. ASLEH K, Lyck Carstensen S, Tykjaer Jorgensen CL, Burugu S, et al
    Basal biomarkers Nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: samples from the phase III SBG0102 clinical trial.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31969.
    PubMed     Text format     Abstract available


  9. MINICOZZI P, Van Eycken L, Molinie F, Innos K, et al
    Comorbidities, age and period of diagnosis influence treatment and outcomes in early breast cancer.
    Int J Cancer. 2018 Nov 8. doi: 10.1002/ijc.31974.
    PubMed     Text format     Abstract available


    October 2018
  10. VAN MAAREN MC, de Munck L, Strobbe LJ, Sonke GS, et al
    10-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study.
    Int J Cancer. 2018 Oct 28. doi: 10.1002/ijc.31914.
    PubMed     Text format     Abstract available


  11. SUN L, Sadique Z, Dos-Santos-Silva I, Yang L, et al
    Cost-effectiveness of Breast Cancer Screening Programme for Women in Rural China.
    Int J Cancer. 2018 Oct 27. doi: 10.1002/ijc.31956.
    PubMed     Text format     Abstract available


  12. BENS A, Cronin-Fenton D, Dehlendorff C, Jensen MB, et al
    Non-aspirin NSAIDs and contralateral breast cancer risk.
    Int J Cancer. 2018 Oct 26. doi: 10.1002/ijc.31949.
    PubMed     Text format    


  13. JOHANSSON ALV, Trewin CB, Hjerkind KV, Ellingjord-Dale M, et al
    Breast cancer-specific survival by clinical subtype after seven years follow-up of young and elderly women in a nationwide cohort.
    Int J Cancer. 2018 Oct 26. doi: 10.1002/ijc.31950.
    PubMed     Text format     Abstract available


  14. HOUGHTON SC, Eliassen AH, Zhang SM, Selhub J, et al
    Plasma B-vitamin and one-carbon metabolites and risk of breast cancer before and after folic acid fortification in the US.
    Int J Cancer. 2018 Oct 22. doi: 10.1002/ijc.31934.
    PubMed     Text format     Abstract available


  15. GIRARD E, Eon-Marchais S, Olaso R, Renault AL, et al
    Familial breast cancer and DNA repair genes: insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.
    Int J Cancer. 2018 Oct 10. doi: 10.1002/ijc.31921.
    PubMed     Text format     Abstract available


  16. BERRANDOU T, Mulot C, Cordina-Duverger E, Arveux P, et al
    Association of breast cancer risk with polymorphisms in genes involved in the metabolism of xenobiotics and interaction with tobacco smoking: a gene-set analysis.
    Int J Cancer. 2018 Oct 10. doi: 10.1002/ijc.31917.
    PubMed     Text format     Abstract available


  17. SHEN Y, Zhang W, Liu J, He J, et al
    Therapeutic Activity of DCC-2036, a Novel Tyrosine Kinase Inhibitor, against Triple-Negative Breast Cancer Patient-Derived Xenografts by Targeting AXL/MET.
    Int J Cancer. 2018 Oct 5. doi: 10.1002/ijc.31915.
    PubMed     Text format     Abstract available


  18. LATTOUF H, Kassem L, Jacquemetton J, Choucair A, et al
    LKB1 regulates PRMT5 activity in breast cancer.
    Int J Cancer. 2018 Oct 5. doi: 10.1002/ijc.31909.
    PubMed     Text format     Abstract available


    September 2018
  19. HARDING C, Pompei F, Burmistrov D, Wilson R, et al
    Long-term relationships between screening rates, breast cancer characteristics, and overdiagnosis in US counties, 1975-2009.
    Int J Cancer. 2018 Sep 28. doi: 10.1002/ijc.31904.
    PubMed     Text format     Abstract available


  20. ELANDS RJ, Offermans NS, Simons CC, Schouten LJ, et al
    Associations of adult-attained height and early life energy restriction with postmenopausal breast cancer risk according to estrogen and progesterone receptor status.
    Int J Cancer. 2018 Sep 25. doi: 10.1002/ijc.31890.
    PubMed     Text format     Abstract available


  21. PARK YM, Steck SE, Fung TT, Merchant AT, et al
    Higher diet-dependent acid load is associated with risk of breast cancer: Findings from the Sister Study.
    Int J Cancer. 2018 Sep 24. doi: 10.1002/ijc.31889.
    PubMed     Text format     Abstract available


  22. HAM SA, Kim E, Yoo T, Lee WJ, et al
    Ligand-activated interaction of PPARdelta with c-Myc governs the tumorigenicity of breast cancer.
    Int J Cancer. 2018 Sep 11. doi: 10.1002/ijc.31864.
    PubMed     Text format     Abstract available


  23. KOMEMI O, Epstein Shochet G, Pomeranz M, Fishman A, et al
    Placenta-conditioned extracellular matrix (ECM) activates breast cancer cell survival mechanisms: A key for future distant metastases.
    Int J Cancer. 2018 Sep 8. doi: 10.1002/ijc.31861.
    PubMed     Text format     Abstract available


  24. JIN ML, Kim YW, Jin HL, Kang H, et al
    Aberrant expression of SETD1A promotes survival and migration of estrogen receptor alpha-positive breast cancer cells.
    Int J Cancer. 2018 Sep 7. doi: 10.1002/ijc.31853.
    PubMed     Text format     Abstract available


  25. FARVID MS, Stern MC, Norat T, Sasazuki S, et al
    Consumption of red and processed meat and breast cancer incidence: a systematic review and meta-analysis of prospective studies.
    Int J Cancer. 2018 Sep 5. doi: 10.1002/ijc.31848.
    PubMed     Text format     Abstract available


  26. LI J, Wen WX, Eklund M, Kvist A, et al
    Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
    Int J Cancer. 2018 Sep 2. doi: 10.1002/ijc.31841.
    PubMed     Text format     Abstract available


    August 2018
  27. YE L, Li F, Song Y, Yu D, et al
    Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of Triple-Negative Breast Cancer.
    Int J Cancer. 2018 Aug 27. doi: 10.1002/ijc.31766.
    PubMed     Text format     Abstract available


  28. MOLLER MH, Lousdal ML, Kristiansen IS, Stovring H, et al
    Effect of organised mammography screening on breast cancer mortality: A population-based cohort study in Norway.
    Int J Cancer. 2018 Aug 25. doi: 10.1002/ijc.31832.
    PubMed     Text format     Abstract available


  29. GAUDET MM, Deubler EL, Kelly RS, Diver WR, et al
    Blood Levels of Cadmium and Lead in Relation to Breast Cancer Risk in Three Prospective Cohorts.
    Int J Cancer. 2018 Aug 17. doi: 10.1002/ijc.31805.
    PubMed     Text format     Abstract available


  30. PEDERSEN MH, Hood BL, Ehmsen S, Beck HC, et al
    CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients.
    Int J Cancer. 2018 Aug 15. doi: 10.1002/ijc.31798.
    PubMed     Text format     Abstract available


  31. CORTESI L, Canossi B, Battista R, Pecchi A, et al
    Breast ultrasonography in the screening protocol for women at hereditary- familial risk of breast cancer: Has the time come to rethink the role of BU according to different risk categories?
    Int J Cancer. 2018 Aug 11. doi: 10.1002/ijc.31794.
    PubMed     Text format     Abstract available


  32. LEE WH, Chen LC, Lee CJ, Huang CC, et al
    DNA primase polypeptide 1 (PRIM1) involves in estrogen-induced breast cancer formation through activation of the G2/M cell cycle checkpoint.
    Int J Cancer. 2018 Aug 11. doi: 10.1002/ijc.31788.
    PubMed     Text format     Abstract available


  33. REUSTLE A, Fisel P, Renner O, Buttner F, et al
    Characterization of the Breast Cancer Resistance Protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
    Int J Cancer. 2018 Aug 2. doi: 10.1002/ijc.31741.
    PubMed     Text format     Abstract available


  34. CHUANG SC, Lin CH, Lu YS, Hsiung CA, et al
    Association of pregnancy and mortality in women diagnosed with breast cancer: A nationwide population based study in Taiwan.
    Int J Cancer. 2018 Aug 2. doi: 10.1002/ijc.31777.
    PubMed     Text format     Abstract available


    July 2018
  35. BASU P, Selmouni F, Belakhel L, Sauvaget C, et al
    Breast Cancer Screening Program in Morocco: Status of implementation, organization and performance.
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31749.
    PubMed     Text format     Abstract available


  36. CLENDENEN TV, Dorgan J, Zeleniuch-Jacquotte A
    Reply to: Anti-Mullerian hormone and breast cancer risk- is the correlation possibly associated with the PCOS?
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31728.
    PubMed     Text format    


  37. TESCH H, Stoetzer O, Decker T, Kurbacher CM, et al
    Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31738.
    PubMed     Text format     Abstract available


  38. MCCORMACK V, Febvey-Combes O, Ginsburg O, Dos-Santos-Silva I, et al
    Breast cancer in women living with HIV: A first global estimate.
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31722.
    PubMed     Text format     Abstract available


  39. BLUMENFELD Z
    Anti-Mullerian hormone and breast cancer risk- is the correlation possibly associated with the PCOS?
    Int J Cancer. 2018 Jul 10. doi: 10.1002/ijc.31732.
    PubMed     Text format    


  40. LAN B, Ma F, Chen S, Wang W, et al
    Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10 T/T genotype breast cancer patients in China.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31639.
    PubMed     Text format     Abstract available


  41. SALEM Y, Yacov N, Propheta-Meiran O, Breitbart E, et al
    Newly Characterized Motile Sperm Domain-Containing Protein 2 Promotes Human Breast Cancer Metastasis.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31665.
    PubMed     Text format     Abstract available


  42. FARVID MS, Chen WY, Rosner BA, Tamimi RM, et al
    Fruit and vegetable consumption and breast cancer incidence: Repeated measures over 30 years of follow-up.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31653.
    PubMed     Text format     Abstract available


  43. PARK YH, Lee KH, Sohn JH, Lee KS, et al
    A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31651.
    PubMed     Text format     Abstract available


  44. VANGANGELT KMH, Tollenaar LSA, van Pelt GW, de Kruijf EM, et al
    The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31658.
    PubMed     Text format     Abstract available


  45. JASKULSKI S, Jung AY, Behrens S, Johnson T, et al
    Circulating enterolactone concentrations and prognosis of postmenopausal breast cancer: Assessment of mediation by inflammatory markers.
    Int J Cancer. 2018 Jul 4. doi: 10.1002/ijc.31647.
    PubMed     Text format     Abstract available


  46. KISO M, Tanaka S, Saji S, Toi M, et al
    Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network.
    Int J Cancer. 2018 Jul 4. doi: 10.1002/ijc.31645.
    PubMed     Text format     Abstract available


    June 2018
  47. LIPTON A, Leitzel K, Ali SM, Polimera HV, et al
    High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts.
    Int J Cancer. 2018 Jun 20. doi: 10.1002/ijc.31627.
    PubMed     Text format     Abstract available


    May 2018
  48. VON NEUBECK B, Gondi G, Riganti C, Pan C, et al
    An inhibitory antibody targeting Carbonic Anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo.
    Int J Cancer. 2018 May 22. doi: 10.1002/ijc.31607.
    PubMed     Text format     Abstract available


  49. WU W, Chen F, Cui X, Yang L, et al
    LncRNA NKILA Suppresses TGF-beta-induced Epithelial-Mesenchymal Transition by Blocking NF-kappaB Signaling in Breast Cancer.
    Int J Cancer. 2018 May 15. doi: 10.1002/ijc.31605.
    PubMed     Text format     Abstract available


  50. LI J, Jing R, Wei H, Wang M, et al
    Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer.
    Int J Cancer. 2018 May 12. doi: 10.1002/ijc.31601.
    PubMed     Text format     Abstract available


  51. TROISI R, Gulbech Ording A, Grotmol T, Glimelius I, et al
    Pregnancy Complications and Subsequent Breast Cancer Risk in the Mother: A Nordic population-based case-control study.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31600.
    PubMed     Text format     Abstract available


  52. LA MANNA S, Lee E, Ouzounova M, Di Natale C, et al
    Mimetics of Suppressor of cytokine signalling 3: novel potential therapeutics in triple breast cancer.
    Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31594.
    PubMed     Text format     Abstract available


  53. OH E, Kim YJ, An H, Sung D, et al
    Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
    Int J Cancer. 2018 May 9. doi: 10.1002/ijc.31585.
    PubMed     Text format     Abstract available


  54. FAN C, Zhang J, Ouyang T, Li J, et al
    RAD50 germline mutations are associated with poor survival in BRCA1/2-negative breast cancer patients.
    Int J Cancer. 2018 May 4. doi: 10.1002/ijc.31579.
    PubMed     Text format     Abstract available


    April 2018
  55. BAGLIA ML, Cook LS, Tang MT, Wiggins C, et al
    Alcohol, Smoking, and Risk of Her2-Overexpressing and Triple-Negative Breast Cancer Relative to Estrogen Receptor-Positive Breast Cancer.
    Int J Cancer. 2018 Apr 30. doi: 10.1002/ijc.31575.
    PubMed     Text format     Abstract available


  56. CAIRAT M, Fournier A, Murphy N, Biessy C, et al
    Nonsteroidal anti-inflammatory drug use and breast cancer risk in a European prospective cohort study.
    Int J Cancer. 2018 Apr 29. doi: 10.1002/ijc.31570.
    PubMed     Text format     Abstract available


  57. LI J, Wang W, Xia P, Wan L, et al
    Identification of a five-lncRNA signature for predicting the risk of tumor recurrence in breast cancer patients.
    Int J Cancer. 2018 Apr 29. doi: 10.1002/ijc.31573.
    PubMed     Text format     Abstract available


  58. AL-AWADHI A, Murray JL, Ibrahim NK
    Developing Anti-HER2 Vaccines: Breast Cancer Experience.
    Int J Cancer. 2018 Apr 25. doi: 10.1002/ijc.31551.
    PubMed     Text format     Abstract available


  59. WILKE CM, Braselmann H, Hess J, Klymenko SV, et al
    A genomic copy number signature predicts radiation exposure in post-Chernobyl breast cancer.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31533.
    PubMed     Text format     Abstract available


  60. BOCK J, Appenzeller S, Haertle L, Schneider T, et al
    Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31526.
    PubMed     Text format     Abstract available


  61. SHAFIEE A, McGovern JA, Lahr CA, Meinert C, et al
    Immune System Augmentation via Humanization Using Stem/Progenitor Cells and Bioengineering in a Breast Cancer Model Study.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31528.
    PubMed     Text format     Abstract available


  62. CAO C, Wu H, Vasilatos SN, Chandran U, et al
    HDAC5-LSD1 Axis Regulates Antineoplastic Effect of Natural HDAC Inhibitor Sulforaphane in Human Breast Cancer Cells.
    Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31419.
    PubMed     Text format     Abstract available


  63. NJOR SH, Paci E, Rebolj M
    As you like it: How the same data can support manifold views of overdiagnosis in breast cancer screening.
    Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31420.
    PubMed     Text format     Abstract available


    March 2018
  64. ERIKSSON L, Bergh J, Humphreys K, Warnberg F, et al
    Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A population-based cohort study.
    Int J Cancer. 2018 Mar 31. doi: 10.1002/ijc.31411.
    PubMed     Text format     Abstract available


  65. YUE W, Wang J, Atkins KA, Bottalico L, et al
    Effect of a tissue selective estrogen complex (TSEC) on breast cancer: Role of unique properties of conjugated equine estrogen.
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31401.
    PubMed     Text format     Abstract available


  66. DE MUNCK L, Fracheboud J, de Bock GH, den Heeten GJ, et al
    Is the incidence of advanced-stage breast cancer affected by whether women attend a steady-state screening program?
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31388.
    PubMed     Text format     Abstract available


  67. GUINTER MA, McLain AC, Merchant AT, Sandler DP, et al
    A dietary pattern based on estrogen metabolism is associated with breast cancer risk in a prospective cohort of postmenopausal women.
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31387.
    PubMed     Text format     Abstract available


  68. GUO W, Key TJ, Reeves GK
    Adiposity and breast cancer risk in postmenopausal women: Results from the UK Biobank prospective cohort.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31394.
    PubMed     Text format     Abstract available


  69. WRIGHT LB, Schoemaker MJ, Jones ME, Ashworth A, et al
    Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study.
    Int J Cancer. 2018 Mar 8. doi: 10.1002/ijc.31364.
    PubMed     Text format     Abstract available


  70. ABUBAKAR M, Chang-Claude J, Ali HR, Chatterjee N, et al
    Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.
    Int J Cancer. 2018 Mar 1. doi: 10.1002/ijc.31352.
    PubMed     Text format     Abstract available


    February 2018
  71. GATHIRUA-MWANGI WG, Song Y, Monahan P, Champion VL, et al
    Associations of Metabolic syndrome and C-reactive protein with Mortality from total cancer, obesity-linked cancers and Breast Cancer among Women in NHANES III.
    Int J Cancer. 2018 Feb 27. doi: 10.1002/ijc.31344.
    PubMed     Text format     Abstract available


  72. LAN B, Ma F, Zhai X, Li Q, et al
    The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
    Int J Cancer. 2018 Feb 3. doi: 10.1002/ijc.31291.
    PubMed     Text format     Abstract available


    January 2018
  73. RIAHI A, Radmanesh H, Schurmann P, Bogdanova N, et al
    Exome sequencing and case-control analyses identify RCC1 as a candidate breast cancer susceptibility gene.
    Int J Cancer. 2018 Jan 24. doi: 10.1002/ijc.31273.
    PubMed     Text format     Abstract available


  74. BUSUND M, Bugge NS, Braaten T, Waaseth M, et al
    Progestin-Only and Combined Oral Contraceptives and Receptor-Defined Premenopausal Breast Cancer Risk: The Norwegian Women and Cancer Study.
    Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31266.
    PubMed     Text format     Abstract available


  75. TERVASMAKI A, Mantere T, Hartikainen JM, Kauppila S, et al
    Rare missense mutations in RECQL and POLG associate with inherited predisposition to breast cancer.
    Int J Cancer. 2018 Jan 17. doi: 10.1002/ijc.31259.
    PubMed     Text format     Abstract available


  76. JOHN EM, Hines LM, Phipps AI, Koo J, et al
    Reproductive history, breast-feeding and risk of triple negative breast cancer: The Breast Cancer Etiology in Minorities (BEM) Study.
    Int J Cancer. 2018 Jan 13. doi: 10.1002/ijc.31258.
    PubMed     Text format     Abstract available


  77. MURTO MO, Artama M, Pukkala E, Visvanathan K, et al
    Breast cancer extent and survival among diabetic women in a Finnish nationwide cohort study.
    Int J Cancer. 2018 Jan 10. doi: 10.1002/ijc.31250.
    PubMed     Text format     Abstract available


  78. GE W, Clendenen TV, Afanasyeva Y, Koenig KL, et al
    Circulating Anti-Mullerian Hormone and Breast Cancer Risk: A Study in Ten Prospective Cohorts.
    Int J Cancer. 2018 Jan 8. doi: 10.1002/ijc.31249.
    PubMed     Text format     Abstract available


  79. BASU P, Ponti A, Anttila A, Ronco G, et al
    Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report.
    Int J Cancer. 2018;142:44-56.
    PubMed     Text format     Abstract available


    December 2017
  80. ANDERSON C, Engel SM, Anders CK, Nichols HB, et al
    Live birth outcomes after adolescent and young adult breast cancer.
    Int J Cancer. 2017 Dec 21. doi: 10.1002/ijc.31227.
    PubMed     Text format     Abstract available


  81. CHEN J, Yao Q, Huang M, Wang B, et al
    A Randomized Phase III Trial of Neoadjuvant Recombinant Human Endostatin, Docetaxel and Epirubicin as First-Line Therapy for Patients with Breast Cancer (CBCRT01).
    Int J Cancer. 2017 Dec 14. doi: 10.1002/ijc.31217.
    PubMed     Text format     Abstract available


  82. XIE X, Tan W, Chen B, Huang X, et al
    Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical-related features for axillary lymph node metastasis in early-stage invasive breast cancer.
    Int J Cancer. 2017 Dec 11. doi: 10.1002/ijc.31208.
    PubMed     Text format     Abstract available


  83. MA L, Fu Q, Xu B, Zhou H, et al
    Breast cancer-associated mitochondrial DNA haplogroup promotes neoplastic growth via ROS-mediated AKT activation.
    Int J Cancer. 2017 Dec 11. doi: 10.1002/ijc.31207.
    PubMed     Text format     Abstract available


  84. DALLASPEZIA S, Cantamessa S, Benedetti F
    Light Therapy and Mood in Breast Cancer.
    Int J Cancer. 2017 Dec 2. doi: 10.1002/ijc.31188.
    PubMed     Text format    


  85. MCKENZIE F, Zietsman A, Galukande M, Anele A, et al
    Drivers of advanced stage at breast cancer diagnosis in the multi-country African Breast Cancer - Disparities in Outcomes (ABC-DO) study.
    Int J Cancer. 2017 Dec 2. doi: 10.1002/ijc.31187.
    PubMed     Text format     Abstract available


    November 2017
  86. LEE KR, Hwang IC, Do Han K, Jung J, et al
    Waist circumference and risk of breast cancer in Korean women: A nationwide cohort study.
    Int J Cancer. 2017 Nov 29. doi: 10.1002/ijc.31180.
    PubMed     Text format     Abstract available


  87. HIS M, Le Guelennec M, Mesrine S, Boutron-Ruault MC, et al
    Life course evolution of body size and breast cancer survival in the E3N cohort.
    Int J Cancer. 2017 Nov 27. doi: 10.1002/ijc.31177.
    PubMed     Text format     Abstract available


  88. JOHANSSON ALV, Andersson TM, Hsieh CC, Jirstrom K, et al
    Tumor characteristics and prognosis in women with pregnancy-associated breast cancer.
    Int J Cancer. 2017 Nov 23. doi: 10.1002/ijc.31174.
    PubMed     Text format     Abstract available


  89. SCHAIRER C, Pfeiffer RM, Gadalla SM
    Autoimmune diseases and breast cancer risk by tumor hormone-receptor status among elderly women.
    Int J Cancer. 2017 Nov 16. doi: 10.1002/ijc.31148.
    PubMed     Text format     Abstract available


  90. BRANDT J, Borgquist S, Almgren P, Forsti A, et al
    Thyroid associated genetic polymorphisms in relation to breast cancer risk in the Malmo Diet and Cancer Study.
    Int J Cancer. 2017 Nov 14. doi: 10.1002/ijc.31156.
    PubMed     Text format     Abstract available


  91. BARRDAHL M, Canzian F, Gaudet MM, Gapstur SM, et al
    A comprehensive analysis of polymorphic variants in steroid hormone and IGF-1 metabolism and risk of in situ breast cancer: results from the Breast and Prostate Cancer Cohort (BPC3) Consortium.
    Int J Cancer. 2017 Nov 7. doi: 10.1002/ijc.31145.
    PubMed     Text format     Abstract available


    October 2017
  92. SCHMIDT ME, Wiskemann J, Schneeweiss A, Potthoff K, et al
    Determinants of physical, affective, and cognitive fatigue: During breast cancer therapy and 12 months follow-up.
    Int J Cancer. 2017 Oct 30. doi: 10.1002/ijc.31138.
    PubMed     Text format     Abstract available


  93. HIRKO KA, Chai B, Spiegelman D, Campos H, et al
    Erythrocyte membrane fatty acids and breast cancer risk: A prospective analysis in the Nurses' Health Study II.
    Int J Cancer. 2017 Oct 26. doi: 10.1002/ijc.31133.
    PubMed     Text format     Abstract available


  94. KEINAN-BOKER L, Levine H, Leiba A, Derazne E, et al
    Adolescent obesity and adult male breast cancer in a cohort of 1,382,093 men.
    Int J Cancer. 2017 Oct 21. doi: 10.1002/ijc.31121.
    PubMed     Text format     Abstract available


  95. YU J, Wang X, Lu Q, Wang J, et al
    Extracellular 5'-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3beta/beta-catenin/cyclinD1 signaling pathway.
    Int J Cancer. 2017 Oct 19. doi: 10.1002/ijc.31112.
    PubMed     Text format     Abstract available


  96. SUROWY H, Varga D, Burwinkel B, Marme F, et al
    A low frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early-onset breast cancer (<60 years) and is associated with reduced DNA repair capacity.
    Int J Cancer. 2017 Oct 16. doi: 10.1002/ijc.31105.
    PubMed     Text format     Abstract available


  97. ZHAO B, Zhao H
    Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor-2-positive breast cancer.
    Int J Cancer. 2017 Oct 11. doi: 10.1002/ijc.31097.
    PubMed     Text format     Abstract available


  98. CONRAD C, Gotte M, Schlomann U, Roessler M, et al
    ADAM8 expression in breast cancer derived metastases: Functional implications on MMP-9 expression and transendothelial migration in breast cancer cells.
    Int J Cancer. 2017 Oct 7. doi: 10.1002/ijc.31090.
    PubMed     Text format     Abstract available


  99. NAGAPRASHANTHA LD, Adhikari R, Singhal J, Chikara S, et al
    Translational Opportunities for Broad-Spectrum Natural Phytochemicals and Targeted Agent Combinations in Breast Cancer.
    Int J Cancer. 2017 Oct 4. doi: 10.1002/ijc.31085.
    PubMed     Text format     Abstract available


    September 2017
  100. THAPA B, Bahadur Kc R, Uludag H
    Novel Targets for Sensitizing Breast Cancer Cells to TRAIL-Induced Apoptosis with siRNA Delivery.
    Int J Cancer. 2017 Sep 27. doi: 10.1002/ijc.31079.
    PubMed     Text format     Abstract available


  101. GUO S, Jing Y, Burcus NI, Lassiter BP, et al
    Nano-Pulse Stimulation Induces Potent Immune Responses, Eradicating Local Breast Cancer while Reducing Distant Metastases.
    Int J Cancer. 2017 Sep 25. doi: 10.1002/ijc.31071.
    PubMed     Text format     Abstract available


  102. WILKE CM, Hess J, Klymenko SV, Chumak VV, et al
    Expression of miRNA-26b-5p and its target TRPS1 is associated with radiation exposure in post-Chernobyl breast cancer.
    Int J Cancer. 2017 Sep 25. doi: 10.1002/ijc.31072.
    PubMed     Text format     Abstract available


  103. KIMBUNG S, Markholm I, Bjohle J, Lekberg T, et al
    Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: results from the phase 2 PROMIX trial.
    Int J Cancer. 2017 Sep 22. doi: 10.1002/ijc.31070.
    PubMed     Text format     Abstract available


  104. KORCH C, Hall EM, Dirks WG, Ewing M, et al
    Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line.
    Int J Cancer. 2017 Sep 22. doi: 10.1002/ijc.31067.
    PubMed     Text format     Abstract available


  105. DE GOOIJER MC, Zhang P, Weijer R, Buil LCM, et al
    The impact of P-glycoprotein and Breast Cancer Resistance Protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.
    Int J Cancer. 2017 Sep 16. doi: 10.1002/ijc.31052.
    PubMed     Text format     Abstract available


  106. WANG S, Huo D, Kupfer S, Alleyne D, et al
    Genetic variation in the Vitamin D related pathway and breast cancer risk in women of African ancestry in the Root Consortium.
    Int J Cancer. 2017 Sep 10. doi: 10.1002/ijc.31038.
    PubMed     Text format     Abstract available


    August 2017
  107. CESPEDES FELICIANO EM, Prentice RL, Aragaki AK, Neuhouser ML, et al
    Methodological Considerations for Disentangling a Risk Factor's Influence on Disease Incidence versus Post-Diagnosis Survival: The Example of Obesity and Breast and Colorectal Cancer Mortality in the Women's Health Initiative.
    Int J Cancer. 2017 Aug 18. doi: 10.1002/ijc.30931.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: